drug_name event_name drug_id event_id drug_and_event_name
2 Glucose Disorder of lung 1560524 257907 Glucose & Disorder of lung
## Chronograph ##

## Basic demographic table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 304 100 Total 1000 100 Total 1000 100 Total 1000 100
Sex gender = FEMALE 181 60 Sex gender = FEMALE 587 59 Sex gender = FEMALE 584 58 Sex gender = FEMALE 546 55
gender = MALE 123 40 gender = MALE 413 41 gender = MALE 416 42 gender = MALE 454 45
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 2 1 (20,30] 7 1 (20,30] 6 1 (20,30] 6 1
(30,40] 7 2 (30,40] 21 2 (30,40] 17 2 (30,40] 14 1
(40,50] 9 3 (40,50] 45 4 (40,50] 32 3 (40,50] 45 4
(50,60] 13 4 (50,60] 72 7 (50,60] 73 7 (50,60] 56 6
(60,70] 65 21 (60,70] 221 22 (60,70] 200 20 (60,70] 224 22
(70,80] 102 34 (70,80] 348 35 (70,80] 346 35 (70,80] 391 39
(80,90] 83 27 (80,90] 225 22 (80,90] 259 26 (80,90] 218 22
(90,110] 23 8 (90,110] 61 6 (90,110] 67 7 (90,110] 46 5
Median 77 IQR=(69, 84) Median 74 IQR=(68, 82) Median 75 IQR=(68, 83) Median 74 IQR=(68, 81)
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 304) % (n = 1,000) Std.Diff Characteristic % (n = 304) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 3.6 0.6 -0.21
25 - 29 0.7 0.7 0.01 Visual system disorder 53.0 35.5 -0.36
30 - 34 0.3 0.4 0.01 Medical history: Cardiovascular disease
35 - 39 1.6 1.5 -0.01 Atrial fibrillation 42.4 27.9 -0.31
40 - 44 1.0 1.5 0.05 Cerebrovascular disease 18.8 11.0 -0.22
45 - 49 2.0 2.8 0.05 Coronary arteriosclerosis 50.0 32.3 -0.37
50 - 54 1.6 2.9 0.08 Heart disease 83.2 60.7 -0.52
55 - 59 1.6 3.9 0.14 Heart failure 43.1 28.0 -0.32
60 - 64 4.9 3.4 -0.08 Ischemic heart disease 24.3 16.1 -0.21
65 - 69 13.5 16.2 0.08 Peripheral vascular disease 45.7 28.6 -0.36
70 - 74 17.1 19.3 0.06 Pulmonary embolism 6.9 3.5 -0.15
75 - 79 16.1 16.1 0.00 Venous thrombosis 13.5 7.7 -0.19
80 - 84 17.8 13.3 -0.12 Medical history: Neoplasms
85 - 89 12.5 10.0 -0.08 Hematologic neoplasm 17.1 10.8 -0.18
90 - 94 4.6 5.1 0.02 Malignant lymphoma 8.6 4.8 -0.15
95 - 99 3.6 2.1 -0.09 Malignant neoplasm of anorectum 3.3 2.3 -0.06
100 - 104 1.0 0.8 -0.02 Malignant neoplastic disease 42.1 29.3 -0.27
Gender: female 59.5 58.7 -0.02 Malignant tumor of breast 7.9 5.5 -0.10
Medical history: General Malignant tumor of colon 9.5 5.3 -0.16
Acute respiratory disease 39.8 23.0 -0.37 Malignant tumor of urinary bladder 5.6 2.8 -0.14
Attention deficit hyperactivity disorder 0.3 0.1 -0.05 Medication use
Chronic liver disease 5.6 1.3 -0.24 Agents acting on the renin-angiotensin system 67.1 69.6 0.05
Chronic obstructive lung disease 12.5 7.5 -0.17 Antibacterials for systemic use 51.6 51.1 -0.01
Crohn’s disease 1.0 1.1 0.01 Antidepressants 65.5 62.2 -0.07
Dementia 20.1 14.4 -0.15 Antiepileptics 37.8 38.2 0.01
Depressive disorder 16.8 11.3 -0.16 Antiinflammatory and antirheumatic products 33.6 35.5 0.04
Diabetes mellitus 74.7 54.4 -0.43 Antineoplastic agents 22.7 13.2 -0.25
Gastroesophageal reflux disease 26.6 14.6 -0.30 Antipsoriatics 0.7 0.4 -0.04
Gastrointestinal hemorrhage 10.5 6.6 -0.14 Antithrombotic agents 63.2 49.1 -0.29
Human immunodeficiency virus infection 0.3 0.8 0.06 Beta blocking agents 61.8 63.6 0.04
Hyperlipidemia 33.2 25.8 -0.16 Calcium channel blockers 50.0 56.8 0.14
Hypertensive disorder 8.2 4.5 -0.15 Diuretics 69.7 67.6 -0.05
Lesion of liver 5.6 3.2 -0.12 Drugs for acid related disorders 55.3 47.9 -0.15
Obesity 10.5 5.9 -0.17 Drugs for obstructive airway diseases 47.0 37.6 -0.19
Osteoarthritis 53.6 36.0 -0.36 Drugs used in diabetes 60.5 62.6 0.04
Psoriasis 2.3 1.4 -0.07 Immunosuppressants 6.9 3.7 -0.14
Renal impairment 39.5 26.6 -0.28 Lipid modifying agents 69.7 72.6 0.06
Rheumatoid arthritis 8.9 6.3 -0.10 Opioids 42.8 33.6 -0.19
Schizophrenia 10.5 6.6 -0.14 Psycholeptics 60.9 52.9 -0.16
Ulcerative colitis 0.7 0.2 -0.07 Psychostimulants, agents used for adhd and nootropics 14.1 14.2 0.00
Urinary tract infectious disease 34.5 20.7 -0.31
## Event vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 2.1 1.8 -0.02
25 - 29 0.4 0.6 0.03 Visual system disorder 50.2 38.1 -0.25
30 - 34 0.7 1.0 0.03 Medical history: Cardiovascular disease
35 - 39 1.1 0.2 -0.11 Atrial fibrillation 43.1 28.1 -0.32
40 - 44 1.1 0.9 -0.02 Cerebrovascular disease 15.8 9.5 -0.19
45 - 49 2.0 3.1 0.07 Coronary arteriosclerosis 48.8 27.4 -0.45
50 - 54 3.3 2.7 -0.04 Heart disease 81.4 57.4 -0.54
55 - 59 3.7 3.0 -0.04 Heart failure 40.9 23.5 -0.38
60 - 64 3.7 2.8 -0.05 Ischemic heart disease 24.8 12.7 -0.31
65 - 69 13.9 15.9 0.06 Peripheral vascular disease 45.4 28.5 -0.36
70 - 74 17.2 22.2 0.13 Pulmonary embolism 5.4 2.8 -0.13
75 - 79 17.8 18.2 0.01 Venous thrombosis 12.8 8.3 -0.15
80 - 84 15.3 13.5 -0.05 Medical history: Neoplasms
85 - 89 11.4 9.9 -0.05 Hematologic neoplasm 16.2 7.0 -0.29
90 - 94 5.0 3.8 -0.06 Malignant lymphoma 7.0 3.6 -0.15
95 - 99 2.8 1.8 -0.07 Malignant neoplasm of anorectum 3.0 2.4 -0.04
100 - 104 0.6 0.4 -0.03 Malignant neoplastic disease 42.9 25.1 -0.38
Gender: female 58.4 54.6 -0.08 Malignant tumor of breast 6.4 2.8 -0.17
Medical history: General Malignant tumor of colon 6.4 4.0 -0.11
Acute respiratory disease 34.6 21.8 -0.29 Malignant tumor of urinary bladder 4.1 2.6 -0.08
Attention deficit hyperactivity disorder 0.1 0.5 0.07 Medication use
Chronic liver disease 3.2 2.9 -0.02 Agents acting on the renin-angiotensin system 44.6 0 -1.27
Chronic obstructive lung disease 15.7 6.9 -0.28 Antibacterials for systemic use 38.0 0 -1.11
Crohn’s disease 0.9 0.8 -0.01 Antidepressants 42.5 0 -1.22
Dementia 19.9 11.3 -0.24 Antiepileptics 24.5 0 -0.81
Depressive disorder 13.3 8.0 -0.17 Antiinflammatory and antirheumatic products 25.2 0 -0.82
Diabetes mellitus 71.1 50.0 -0.44 Antineoplastic agents 15.7 0 -0.61
Gastroesophageal reflux disease 24.2 13.7 -0.27 Antipsoriatics 0.7 0 -0.12
Gastrointestinal hemorrhage 11.4 6.4 -0.18 Antithrombotic agents 38.1 0 -1.11
Human immunodeficiency virus infection 1.2 0.5 -0.08 Beta blocking agents 42.1 0 -1.21
Hyperlipidemia 36.7 24.9 -0.26 Calcium channel blockers 32.8 0 -0.99
Hypertensive disorder 5.7 4.8 -0.04 Diuretics 45.9 0 -1.30
Lesion of liver 7.3 3.4 -0.17 Drugs for acid related disorders 32.6 0 -0.98
Obesity 9.0 5.0 -0.16 Drugs for obstructive airway diseases 29.4 0 -0.91
Osteoarthritis 56.1 39.1 -0.35 Drugs used in diabetes 36.7 0 -1.08
Psoriasis 1.6 1.8 0.02 Immunosuppressants 4.7 0 -0.31
Renal impairment 38.4 22.0 -0.36 Lipid modifying agents 46.8 0 -1.33
Rheumatoid arthritis 10.3 6.2 -0.15 Opioids 28.6 0 -0.90
Schizophrenia 7.4 3.7 -0.16 Psycholeptics 41.9 0 -1.20
Ulcerative colitis 0.7 0.2 -0.07 Psychostimulants, agents used for adhd and nootropics 11.2 0 -0.50
Urinary tract infectious disease 33.2 17.9 -0.36
## Drug vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 2.1 1.8 -0.02
25 - 29 0.4 0.6 0.03 Visual system disorder 50.2 38.1 -0.25
30 - 34 0.7 1.0 0.03 Medical history: Cardiovascular disease
35 - 39 1.1 0.2 -0.11 Atrial fibrillation 43.1 28.1 -0.32
40 - 44 1.1 0.9 -0.02 Cerebrovascular disease 15.8 9.5 -0.19
45 - 49 2.0 3.1 0.07 Coronary arteriosclerosis 48.8 27.4 -0.45
50 - 54 3.3 2.7 -0.04 Heart disease 81.4 57.4 -0.54
55 - 59 3.7 3.0 -0.04 Heart failure 40.9 23.5 -0.38
60 - 64 3.7 2.8 -0.05 Ischemic heart disease 24.8 12.7 -0.31
65 - 69 13.9 15.9 0.06 Peripheral vascular disease 45.4 28.5 -0.36
70 - 74 17.2 22.2 0.13 Pulmonary embolism 5.4 2.8 -0.13
75 - 79 17.8 18.2 0.01 Venous thrombosis 12.8 8.3 -0.15
80 - 84 15.3 13.5 -0.05 Medical history: Neoplasms
85 - 89 11.4 9.9 -0.05 Hematologic neoplasm 16.2 7.0 -0.29
90 - 94 5.0 3.8 -0.06 Malignant lymphoma 7.0 3.6 -0.15
95 - 99 2.8 1.8 -0.07 Malignant neoplasm of anorectum 3.0 2.4 -0.04
100 - 104 0.6 0.4 -0.03 Malignant neoplastic disease 42.9 25.1 -0.38
Gender: female 58.4 54.6 -0.08 Malignant tumor of breast 6.4 2.8 -0.17
Medical history: General Malignant tumor of colon 6.4 4.0 -0.11
Acute respiratory disease 34.6 21.8 -0.29 Malignant tumor of urinary bladder 4.1 2.6 -0.08
Attention deficit hyperactivity disorder 0.1 0.5 0.07 Medication use
Chronic liver disease 3.2 2.9 -0.02 Agents acting on the renin-angiotensin system 44.6 0 -1.27
Chronic obstructive lung disease 15.7 6.9 -0.28 Antibacterials for systemic use 38.0 0 -1.11
Crohn’s disease 0.9 0.8 -0.01 Antidepressants 42.5 0 -1.22
Dementia 19.9 11.3 -0.24 Antiepileptics 24.5 0 -0.81
Depressive disorder 13.3 8.0 -0.17 Antiinflammatory and antirheumatic products 25.2 0 -0.82
Diabetes mellitus 71.1 50.0 -0.44 Antineoplastic agents 15.7 0 -0.61
Gastroesophageal reflux disease 24.2 13.7 -0.27 Antipsoriatics 0.7 0 -0.12
Gastrointestinal hemorrhage 11.4 6.4 -0.18 Antithrombotic agents 38.1 0 -1.11
Human immunodeficiency virus infection 1.2 0.5 -0.08 Beta blocking agents 42.1 0 -1.21
Hyperlipidemia 36.7 24.9 -0.26 Calcium channel blockers 32.8 0 -0.99
Hypertensive disorder 5.7 4.8 -0.04 Diuretics 45.9 0 -1.30
Lesion of liver 7.3 3.4 -0.17 Drugs for acid related disorders 32.6 0 -0.98
Obesity 9.0 5.0 -0.16 Drugs for obstructive airway diseases 29.4 0 -0.91
Osteoarthritis 56.1 39.1 -0.35 Drugs used in diabetes 36.7 0 -1.08
Psoriasis 1.6 1.8 0.02 Immunosuppressants 4.7 0 -0.31
Renal impairment 38.4 22.0 -0.36 Lipid modifying agents 46.8 0 -1.33
Rheumatoid arthritis 10.3 6.2 -0.15 Opioids 28.6 0 -0.90
Schizophrenia 7.4 3.7 -0.16 Psycholeptics 41.9 0 -1.20
Ulcerative colitis 0.7 0.2 -0.07 Psychostimulants, agents used for adhd and nootropics 11.2 0 -0.50
Urinary tract infectious disease 33.2 17.9 -0.36
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
antithrombotic agents 384
beta blocking agents 376
alimentary tract and metabolism 275
nervous system 275
cardiovascular system 272
all other therapeutic products 248
blood and blood forming organs 246
respiratory system 234
antiepileptics 230
analgesics 218
antihistamines for systemic use 214
ophthalmologicals 213
sensory organs 213
diuretics 212
lipid modifying agents 212
lipid modifying agents, plain 212
psychoanaleptics 211
systemic hormonal preparations, excl. sex hormones and insulins 207
agents acting on the renin-angiotensin system 204
antidepressants 199
hmg coa reductase inhibitors 194
psycholeptics 185
drugs used in diabetes 184
stomatological preparations 184
blood glucose lowering drugs, excl. insulins 182
cond_180_days n_180_days
heart disease 253
pain 251
pain finding at anatomical site 246
inflammation of specific body systems 244
arthropathy 242
measurement finding outside reference range 234
inflammation of specific body organs 233
vascular disorder 228
diabetes mellitus 227
soft tissue lesion 214
type 2 diabetes mellitus 211
pain of truncal structure 197
abnormal blood cell count 186
measurement finding below reference range 183
structural disorder of heart 183
neoplastic disease 178
cytopenia 177
erythropenia 177
rbc count abnormal 177
rbc count low 177
cardiac arrhythmia 176
hemoglobin level outside reference range 176
hemoglobin low 176
anemia 175
arteriosclerotic vascular disease 173